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Neoadjuvant trials in early breast cancer:
pathological response at surgery and correlation
to longer term outcomes – what does it all
mean?
Helena Earl1,2,3,4*, Elena Provenzano2,3,4, Jean Abraham1,2,3,4, Janet Dunn5, Anne-Laure Vallier3,4,
Ioannis Gounaris4,6 and Louise Hiller5
Abstract
Background: Neoadjuvant breast cancer trials are important for speeding up the introduction of new treatments
for patients with early breast cancer and for the highly productive translational research which they facilitate.
Meta-analysis of trial data shows clear correlation between pathological response at surgery after neoadjuvant
chemotherapy and longer-term outcomes at an individual patient level. However, this does not appear to be
present on individual trial level analysis, when correlating improved outcome for the investigational arm for
the primary endpoint (pathological response) with longer-term outcomes.
Discussion: The correlation between pathological response and longer-term outcomes in trials is dependent on
many factors. These include definitions of pathological response, both complete and partial; assessment methods for
pathological response at surgery; subtype and prognosis of breast cancer at diagnosis; number of patients recruited;
adjuvant treatments; the mechanism of action of the investigational drug; the length of follow-up at the time of
reporting; the definitions used in longer-term outcomes analysis; clonal heterogeneity; and new adaptive trial designs
with additional neo/adjuvant treatments. Future developments of neoadjuvant breast cancer trials are discussed. With
so many factors influencing the correlation of longer-term outcomes for trial-level data, we conclude that the main
focus of neoadjuvant trials should remain the primary endpoint of pathological response.
Summary: Neoadjuvant breast cancer trials are very important investigational studies that will continue to increase our
understanding of the disease and offer the potential of more rapid introduction of new treatments for women with
high-risk early breast cancer. In the future, we are likely to see both novel trial designs adopted in the neoadjuvant
context and modifications of neo/adjuvant treatments for pathological non-responders within clinical trials. Both of
these have the intention of improving longer-term outcomes for patients who do not have a good pathological
response to first-line neoadjuvant treatment. If successful, these developments are likely to reduce further any positive
correlation between pathological response and longer-term outcomes.
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Background
Neoadjuvant treatment of early breast cancer has
many advantages both for patients and for the ‘rich’
track of clinical, translational and scientific research
that can be carried out. Published evidence confirms
a reduction in mastectomy rates with increasing use
of neoadjuvant therapy both on a population [1] and
individual trial basis [2–4]. The relationship between
pathological response and longer-term outcome in
women with early breast cancer receiving neoadju-
vant systemic therapy is highly complex and its' de-
pendencies are multifactorial. This opinion article
discusses the relationship between the two. A recent
meta-analysis of neoadjuvant breast cancer trials [5]
and a meta-regression of trials data [6] have con-
firmed in just short of fifteen thousand women the
robust relationship between achieving a pathological
response (particularly a complete pathological re-
sponse, pCR) and improved longer-term outcomes on
an individual patient level (Fig. 1). We will explore
the factors that, for the trial level question, influence
the relationship between the primary endpoint (pCR)
and the longer-term outcomes. We also explore why,
on an individual trial level analysis, any correlation
between improved outcome for the investigational
trial arm—in terms of the primary endpoint (pathological
response)—and longer term outcomes seems more
challenging to establish [5–8], with very few excep-
tions [9, 10]. Nevertheless, our opinion is that neoad-
juvant treatments and trials should retain their place
at the forefront of research and treatment for high-
risk early breast cancer.
Discussion
What do we mean when we say pathological complete
response?
Neoadjuvant clinical trials, using pCR as an evaluable
endpoint, have gained acceptance as a means of the ini-
tial evaluation of the efficacy of new agents. However,
comparison of outcomes of these trials is currently diffi-
cult, because different trials use different definitions of
pCR. Many early neoadjuvant trials looked at response
in the breast only, and defined pCR as no residual inva-
sive disease in the breast, irrespective of the presence of
ductal carcinoma in situ (DCIS) or nodal involvement
(ypT0/is ypNx). Some later trials used a more stringent
definition that included response in both the breast and
the axillary lymph nodes, either allowing the presence of
residual DCIS (ypT0/is ypN0) or requiring absence of
both invasive disease and DCIS in the breast (ypT0 ypN0).
A meta-analysis of 12 major neoadjuvant randomised
trials involving 11,955 patients was undertaken by the
Collaborative Trials in Neoadjuvant Breast Cancer
(CTNeoBC) Group [5]. They examined the different def-
initions of pCR, with overall pCR rates of 22 % for
ypT0/is ypNx, 18 % for ypT0/is ypN0 and 13 % for ypT0
ypN0. Event-free and overall survival (OS) was found to
be significantly worse for the group with residual nodal
involvement and similar in the remaining two groups
without residual invasive cancer in breast and lymph
nodes regardless of the presence or absence of DCIS
(Fig. 2). As a result, the US Food and Drug Administration
(FDA) have advocated use of either ypT0 ypN0 or ypT0/is
ypN0 as definitions of pCR in their guidance on the use of
pCR as an endpoint for accelerated approval for agents in
Fig. 1 Associations between pathological complete response and event-free survival and overall survival. The ypT0/is ypN0 definition of pathological
complete response was used (i.e. absence of invasive cancer in the breast and axillary nodes, irrespective of ductal carcinoma in situ). CI confidence
interval, HR hazard ratio. (Reproduced with permission from The Lancet, Cortazar et al. [5]: License Number 3666940645625)
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the neoadjuvant treatment of aggressive early breast
cancer [11, 12].
There is general consensus that the definition of pCR
should include axillary lymph node status, because several
studies have shown that residual disease in the axillary
lymph nodes indicates a worse prognosis, even in the
presence of pCR in the breast [13–15]. In both the neo-
tAnGo and MD Anderson series, this group represented
around 4 % of patients [15, 16]. Potential explanations in-
clude sampling error in the breast, due to extensive size or
inaccurate localisation of the primary tumour bed, or
presence of a resistant sub-clone in the metastasis.
The issue of whether DCIS should be included in the def-
inition of pCR is more contentious. A single-institution co-
hort study of patients from the MD Anderson Cancer
Center showed no difference in survival between patients
with and without residual DCIS, similar to the CTNeoBC
meta-analysis [5, 17]. However, a pooled analysis of seven
prospective neoadjuvant clinical trials performed by the
German and Austrian Breast Groups found significantly lon-
ger disease-free survival in patients without residual DCIS
(hazard ratio [HR] 1.74; p < 0.001), with a non-significant
trend towards increased OS (HR 1.41, p= 0.166) [18].
The definition of pCR used should be clearly stated in the
pathology report. Regardless of which definition is used, the
presence of residual DCIS and nodal metastasis should be
recorded and quantified as per the adjuvant setting.
Why is histologic assessment and quantification of
residual disease important?
The likelihood of pCR in breast cancer is heavily influ-
enced by the biological subtype. Breast cancers that are
low grade and oestrogen receptor (ER)- and progester-
one receptor (PR)-positive and human epidermal growth
factor receptor 2 (HER2)-negative have the lowest rates
of pCR (<10 %), with a weaker association between not
achieving a pCR and survival outcomes. In contrast,
HER2-positive/ER-negative and triple-negative (ER/PR/
HER2-negative) breast cancers show much higher rates
of pCR, with a stronger association between not achiev-
ing a pCR and poorer outcome (Fig. 3).
Residual disease includes a broad spectrum of re-
sponses, from excellent response with minimal disease
measuring only a few millimetres, to no response or
even progression of disease on chemotherapy. In order
to refine and maximise the prognostic utility of response
to neoadjuvant chemotherapy, accurate evidence-based
stratification of the group of patients with partial re-
sponse is essential. To achieve this, there needs to be
better standardisation of specimen handling and histo-
logical reporting of neoadjuvant breast cancer speci-
mens. The BIG-NABCG Residual Disease Working
Group has recently formulated recommendations for the
standardised pathological evaluation and reporting of
neoadjuvant breast cancer specimens, which will hope-
fully facilitate accurate comparison of treatment out-
comes within and across clinical trials [19]:
(1)Specimen handling: Specimen handling incorporates
macroscopic description, slicing and sampling of the
surgical specimen (ideally including samples for
translational research). Following neoadjuvant
chemotherapy, the residual tumour may be difficult to
detect on gross examination, particularly when there
Fig. 2 Associations between three definitions of pathological complete response and event-free survival and overall survival. We compared event-free
survival and overall survival between patients who did and did not achieve a pathological complete response according to one of three definitions.
Patients who did not achieve pathological complete response are not shown. The number of patients who achieved a pathological complete response
is listed for each pathological complete response definition. Patients could achieve pathological complete response according to more than one
definition. ypT0ypN0 = absence of invasive cancer and in situ cancer in breast and axillary nodes. ypT0/is ypN0 = absence of invasive cancer in breast
and axillary nodes, irrespective of ductal carcinoma in-situ. ypT0/is = absence of invasive cancer in breast, irrespective of ductal carcinoma in-situ or
nodal involvement. CI confidence interval, HER2 human epidermal growth factor receptor 2, HR hazard ratio. (Reproduced with permission from The Lancet,
Cortazar et al. [5]: License Number 3666940645625)
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Fig. 3 Percentage of patients achieving pathological complete response (a) and HRs for overall survival (b), by subgroup.Information about
clinical tumour stage available for 11 869 patients, about clinical nodal status for 11 807 patients, about histological type for 10,263 patients, about
tumour grade for 8035 patients, and about clinical subtype for 5694 patients. ypT0/isypN0 definition of pathological complete response used. No
multiplicity adjustment was made. HR hazard ratio, CI confidence interval, HER2 human epidermal growth factor receptor 2. (Reproduced with
permission from The Lancet, Cortazar et al. [5]: License Number 3666940645625)
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has been an excellent clinical response and there may
be no macroscopic lesion at all or only a vague
area of fibrosis. Good multi-disciplinary team
communication, provision of accurate clinical
notes, and macroscopic correlation with clinical
and imaging findings is essential to ensure the
correct area is sampled. Placement of marker clips
in the tumour bed before commencement of therapy,
even in patients undergoing mastectomy, is invaluable
for accurate localisation of the tumour bed.
(2)Grading response: There are numerous systems in
the literature for grading of response post neoadjuvant
chemotherapy; these have been reviewed in detail
elsewhere [20–23]. The main systems are summarised
in Table 1. There are two main approaches to
assessment of residual disease post chemotherapy.
Sometimes tumour size does not decrease but there
may be a marked reduction in tumour cellularity. The
first approach involves comparison of the tumour
cellularity pre and post treatment, giving an estimate
of tumour response to treatment. Systems that use
this approach include the Sataloff, Chevallier,
Miller-Payne and Pinder systems [21, 24–26]. The
presence of response in both the breast and lymph
nodes should be noted. Disadvantages are that
comparison with the pre-treatment core biopsy is
required and this may not always be available, and
there is no indication of the extent of residual disease.
The Residual Cancer Burden score (RCB) is an alter-
native approach that quantifies the volume of residual
disease remaining following neoadjuvant therapy, rather
than actual response per se [27]. The score is derived
from the size of the residual invasive cancer measured in
two dimensions, residual tumour cellularity and propor-
tion of in situ disease estimated by review of up to five
slides representing the maximum tumour dimension, the
number of involved nodes and the size of largest metas-
tasis. The values can be entered into an online calculator
available at [28] that provides the RCB score and class
(0–III). The RCB is relatively simple to apply, reprodu-
cible, and has been validated with longer-term clinical
follow-up data [29]. The RCB score has been advocated
as the preferred system for use in clinical trials [19], be-
cause partial response is calculated as a continuous vari-
able that may provide more information regarding the
relationship between pathological residual disease and
clinical outcomes than looking at pCR alone.
To illustrate how the different definitions of patho-
logical response can alter the headline results for a trial,
we include here results from our recently published
ARTemis trial [4], demonstrating results for ypT0/is
ypN0, ypT0/is and ypT0/is plus minimal residual disease
in the breast only (Table 2) for different groups of
patients. The most important difference may be for
those patients with pCR in the breast but with disease in
axillary lymph nodes, because these patients seem to
have longer-term outcomes more in keeping with those
of patients who do not achieve a pCR in the breast. This
means that if they are included in the pCR longer-
term outcome correlation an additional bias will be
introduced.
In summary, in the meta-analysis of neoadjuvant
chemotherapy trials carried out by the US FDA, the def-
inition of pCR that is endorsed is absence of residual in-
vasive disease in the breast and axillary lymph nodes
either ypT0 ypN0 or ypT0/is ypN0. This is the accepted
definition that should be used in reporting neoadjuvant
clinical trials in the future. The definition of the degree
of residual disease in the breast and axillary lymph nodes
is not uniformly agreed, although the RCB [27] score
described here is being increasingly used.
What influences the relationship between pCR and
longer-term outcomes in neoadjuvant breast cancer?
Definition of pCR and review
How the definition of pathological response used within
neoadjuvant trials is arrived at is rarely included in the
reports. An ideal would be to have a central pathological
review of each case in full although this is unlikely to be
practical in the timeframes and with the samples avail-
able. In Neo-tAnGo [7] and ARTemis [4], we carried out
a two-reader blinded report review as described in
Provenzano et al. [23], with further review of the reports
when the two readers disagreed to obtain consensus.
Our neoadjuvant group feels confident that this is a ro-
bust enough strategy for determining pCR for each pa-
tient. We will have the opportunity to test this in the
ARTemis trial, in which we have a completed report re-
view [4] and a central pathology review in progress.
It is essential to include the definition of pCR that was
used within a trial in the paper, and to report all import-
ant data (residual DCIS and axillary node status). This
will allow accurate meta-analysis with reference to the
different definitions, even if the headline results are not
completely harmonised in each trial report.
Type of breast cancer and prognostic and predictive factors
The biology of the type of breast cancer (e.g. ER-positive
HER2-positive) will influence the pCR rate and often the
effect size between a control arm and an experimental
arm. The meta-analysis manuscript [5] shows clearly
that the pCR rate increases the higher the biological risk
(Fig. 3). In ER-positive low-grade cancers, achieving a
pCR predicts an excellent outcome as it does in high-
risk disease/biology, however, varying degrees of patho-
logic response has less prognostic value than in other
subtypes. As an example, the HR for OS for those
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Table 1 Classification systems of pathological response to neoadjuvant breast cancer treatment
Classification system Comment
American Joint Committee on Cancer/Union for International Cancer Control staging system 7th edition
ypT ypN, same categories as for adjuvant setting No evaluation of response;
No published data relating current edition definitions to survival
outcomes
Chevallier
Class 1. No invasive carcinoma or DCIS, negative lymph nodes Class 1 and 2 = pCR (DCIS allowed)
Class 2. DCIS in the breast, no invasive carcinoma, negative lymph nodes
Class 3. Invasive carcinoma with stromal alteration
Class 4. Few modifications of tumour appearance
Sataloff
Tumour: T-A includes pCR and minimal residual disease
T-A. Total or near total therapeutic effect T-A versus other categories associated with survival outcomes
T-B. >50 % therapeutic effect, but less than T-A
T-C. <50 % therapeutic effect
T-D. No therapeutic effect
Nodes:
N-A. Evidence of therapeutic effect, no metastasis
N-B. No nodal metastasis or therapeutic effect
N-C. Evidence of therapeutic effect, but metastasis present
N-D. Metastatic disease, no therapeutic effect
Miller Payne
Grade 1. No reduction in overall cellularity DCIS allowed for pCR
Grade 2. Minor loss of tumour cells (up to 30 %) Does not include response in the lymph nodes
Grade 3. 30–90 % reduction in tumour cellularity Association with survival outcomes
Grade 4. >90 % loss of tumour cellularity
Grade 5. No malignant cells identifiable; DCIS may be present
Pinder
Breast: DCIS allowed for pCR
1. pCR: (1) no residual carcinoma or (2) no residual invasive tumour but DCIS
present.
2. Partial response: (1) minimal residual disease ( <10 % of tumour remaining) ,
(2) evidence of response with 10–50 % of tumour remaining or (3) >50 % of
tumour cellularity remaining with some features of response present.
3. No evidence of response to therapy.
Lymph nodes: Practical approach which is easy to apply
1. No evidence of metastasis or response. No published data regarding association with survival outcomes
2. Metastases not present but evidence of response.
3. Metastasis present with evidence of response.
4. Metastasis present with no evidence of response.
Residual Cancer Burden score
Combines tumour size in two dimensions, average residual cellularity, number of
involved nodes and size of largest metastases. Online calculator to generate a
continuous numerical index that is subdivided into four classes (0 = pCR, I, II and III).
Quantifies residual disease rather than evaluates response
Reproducible and relatively easy to apply
Validated in several independent cohorts
Significant association with survival outcomes over long term
follow up
DCIS ducal carcinoma in situ, pCR complete pathological response
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achieving pCR is 0.16 (95 % confidence interval [CI]
0.11–0.25) in triple-negative cancers but only 0.47
(95 % CI 0.21–1.07) for low grade ER-positive HER2-
negative ones. This difference may relate to additional
adjuvant hormonal treatments given to ER-positive
patients as well as the different biology, for which a
continued, although small, risk of relapse is present.
Small sample numbers
Neoadjuvant trials are powered for the primary endpoint
of pCR and not for secondary endpoints such as relapse-
free survival (RFS) and OS. On a purely statistical basis,
unless the benefit in pCR rate is very large, there is
unlikely to be a statistically significant result for the trial
question in RFS and OS endpoints.
Adjuvant treatment
Any adjuvant treatment given after surgery in neoadju-
vant trials is likely to influence longer-term outcomes,
and clearly this effect will be greatest in patients who
have not achieved a pCR at the time of surgery. Adju-
vant treatments include 5–10 years of hormonal treat-
ment in ER-positive disease, and anti-HER2 therapy in
HER2-positive disease. Trials of new targeted agents in
the adjuvant setting will also confound the relationship
between pCR and longer-term outcomes, particularly if
used to treat exclusively the non-pCR group. However,
the outcome to be achieved here is for maximum patient
benefit and our view is that patients who do not achieve
a significant pathological response should have the op-
portunity to enter new clinical trials designed to test
additional adjuvant treatments in non-responders. In the
future it may be better to include mainly high-risk pa-
tients in neoadjuvant chemotherapy trials, identified by
molecular markers of high-risk biology and predictive
biomarkers of chemotherapy sensitivity. Patients with
low-risk, ER-positive, HER2-negative cancers will all re-
ceive effective adjuvant hormonal treatments that influ-
ences the correlation between pathological response
(especially for non-responders) and longer-term out-
comes. For patients with low-risk but large ER-positive
breast cancers, an alternative neoadjuvant management
is to use hormonal treatments with a view to improving
the rates of breast conservation.
Length of follow-up and interaction with type of breast
cancer and prognosis
Length of follow-up in neo/adjuvant early breast cancer
trials is a further factor influencing longer-term results.
This has been reviewed for adjuvant breast cancer trial
reporting [30], and the same arguments would hold for
correlation between pCR and longer-term outcomes. In
trials including both patients with ER-positive and ER-
negative tumours, because the events for patients with
ER-negative cancers tend to be mostly in the first 3 years,
once the Kaplan–Meier curves have stabilised they will
change little. Conversely, patients with ER-positive can-
cers continue to have a steady (albeit low) rate of events,
which means that the longer the follow-up, the more
widely the curves will separate. Therefore, length of
follow-up at the time of analysis can influence the ob-
served relationship between pCR and RFS and OS; more
importantly, for a given improvement in pCR rate
between trial arms, the magnitude and direction of
this bias will depend on the specific trial population
stratification.
Definition of longer-term outcomes
We have talked generally about ‘longer-term outcome’
but the definition of this provides additional complexity
when correlating with pCR. Disease-free survival com-
monly includes local recurrence in breast or local lymph
nodes, the development of a new primary in the same or
contralateral breast, the appearance of a second
Table 2 Pathological complete response and minimal residual
disease in response to D-FEC and Bev + D-FEC – ARTemis trial
D→ FEC Bev + D→ FEC
% (95 % CI) % (95 % CI) p valuea
pCR in all breast tumours and
absence of disease in all
removed axillary lymph nodes
(ypT0/Tis ypN0)b
(n = 66/393) (n = 87/388) 0.03
17 % (13–21 %) 22 % (18–27 %)
ER negative (Allred 0–2)
(n = 241)
31 % (23–40) 45 % (36–55)
ER weakly positive (Allred 3–5)
(n = 74)
30 % (16–47) 51 % (34–68)
ER strongly positive (Allred 6–8)
(n = 466)
7 % (4–11) 6 % (3–10)
pCR in all breast tumours
(ypT0/Tis)
(n = 76/394) (n = 99/388) 0.02
19 % (16–24) 26 % (21–30)
ER negative (Allred 0–2)
(n = 241)
34 % (25–43) 49 % (39–58)
ER weakly positive (Allred 3–5)
(n = 75)
39 % (24–57) 59 % (42–75)
ER strongly positive (Allred 6–8)
(n = 466)
9 % (5–13) 8 % (5–12)
pCR or minimal residual disease
in all breast tumours
(n = 114/394) (n = 138/388) 0.03
29 % (25–34 %) 36 % (31–41 %)
ER negative (Allred 0–2)
(n = 241)
44 % (35–54) 58 % (49–67)
ER weakly positive (Allred 3–5)
(n = 75)
50 % (33–67) 70 % (53–84)
ER strongly positive (Allred 6–8)
(n = 466)
18 % (13–23) 19 % (14–24)
aAdjusted for the five stratification variables (age [≤50, >50 years old], ER status
[negative, weakly positive, strongly positive], tumour size [≤50, >50 mm], clinical
involvement of axillary nodes [no, yes], and inflammatory or locally advanced
disease [no, yes])
bPrimary endpoint for the ARTemis trial
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malignancy, and distant metastatic disease. RFS com-
monly includes all of the above except the development
of a new second malignancy. For neoadjuvant trials and
for correlation of pCR we are most interested in distant
metastases free survival (DMFS), i.e. recurrence pertin-
ent to the breast cancer we have treated. In terms of
mortality indicators, breast cancer-specific survival
(BCSS), i.e. death caused by breast cancer metastases, is
more relevant than OS. In neoadjuvant trials, BCSS and
OS are likely to be very similar because these trials gen-
erally do not include older patients with comorbidities
that in larger adjuvant hormone trials will be causing
additional deaths. An interesting demonstration of how
much difference BCSS compared with OS makes to ana-
lysis of large patient numbers is the follow-on analysis of
nearly 2,000 patients included in the intrinsic cluster
breast cancer subtypes [31]. The longer the follow-up,
the more effect from ‘all-cause mortality’ will be seen,
which will impact to a greater degree in lower-risk pa-
tients. Therefore, with longer follow-up, non-cancer
mortality disproportionately distorts the outcomes of
lower-risk patients who do not die because of cancer
and are relatively more exposed to these competing
risks.
The possible effect of clonal heterogeneity
There is increasing appreciation of clonal heterogeneity
within ‘solid’ cancers that is probably present at the time
of diagnosis in the primary lesion. In their seminal paper
in 1979, Goldie and Coldman described mathematical
models and hypotheses for spontaneous mutation rates
in cancers, dependent on size, that were related to
chemotherapy sensitivity and resistance [32]. It is pos-
sible, even likely, that clones which form the basis of
micro-metastatic disease will be different from the dom-
inant clones in the primary tumour. This is currently a
field of intense activity in translational and scientific re-
search. If metastatic disease were to be significantly dif-
ferent in terms of treatment sensitivity from the start,
then any hoped-for correlation between the response of
the primary tumour (pCR) and longer-term outcomes
would be lost. This area of translational research will be
greatly helped by analysis of circulating tumour cells
(and circulating tumour DNA within neoadjuvant trials.
Based on the work of Dawson et al. [33], we now include
these translational analyses in all our neoadjuvant stud-
ies. We are optimistic that this will allow us to identify
the small group of patients who have persistent micro-
metastatic disease despite achieving a pCR, and the
perhaps larger group of patients in whom, although
pathological response is not complete, eradication of
micro-metastatic disease is observed at the time of sur-
gery. By means of this technology, over the next decade
our ability to know at a molecular level what is
happening in each individual patient will be enormously
enhanced. Whilst all our dreams of personalising tar-
geted therapy for our patients may not materialise, it
may prove that circulating DNA and circulating tumour
cell assays after neoadjuvant therapy and surgery may be
helpful in defining those patients who require additional
adjuvant treatment and those who do not, regardless of
the response status of the primary tumour and lymph
nodes after neoadjuvant treatment.
Is bevacizumab a special case?: exploring the effect on the
relationship between pCR and long-term cancer-related
outcomes for a ‘pure’ angiogenesis inhibition
Reports of neo/adjuvant use of bevacizumab in early
breast cancer have produced added complexity when
examining the correlation between pCR and longer-term
cancer-related outcomes. Four neoadjuvant trials,
GeparQuinto [34], NSABP-B40 [35], CALGB 40603
(Alliance – Triple negative) [36] and ARTemis [4], all
show a significant improvement in pCR with bevacizu-
mab. For the purposes of comparative analysis, these trials
exclude patients with HER2-positive tumours, which
means that the biological differences (discussed in an
earlier section) between the cohorts (i.e. ER-positive/
HER2-negative and ER-negative/HER2-negative groups)
are considerable. Whilst GeparQuinto, CALGB 40603 and
ARTemis all show effect in the triple-negative group, the
NSABP-B40 trial shows a significant effect in the ER-
positive cohort. In terms of correlation with longer-term
outcomes, the GeparQuinto group has now published on
RFS and OS [8] and shows no correlation between the im-
proved pCR rates and longer-term outcomes. In addition,
two large adjuvant bevacizumab trials, BEATRICE
(TNBC) and ECOG Study E5103 (HER2-negative), show
no benefit from the addition of 12 months’ bevacizumab
therapy to adjuvant chemotherapy [37, 38]. In our opin-
ion, bevacizumab, acting as a ‘pure’ angiogenesis inhibitor,
has the potential to improve rates of pCR in the primary
tumour, which is angiogenesis-dependent, but has no such
effect in the putatively angiogenesis-independent micro-
metastatic disease, particularly in the bone marrow.
Whilst adjuvant bevacizumab may delay the development
of established metastatic disease during the 12 months of
treatment, its lack of a direct anti-cancer effect makes it
unlikely to eliminate micro-metastatic disease if it is
present. The lack of efficacy in terms of RFS and OS in
the adjuvant trials would support this hypothesis [37, 38].
At present, the report of longer-term outcomes from the
NSABP-B40 [9] does not support this hypothesis because
it demonstrates improved longer-term outcomes with
bevacizumab in the ER-positive group when both neoad-
juvant and adjuvant treatment is given. However, as dis-
cussed in the previous section, it may be too early to
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analyse long-term outcomes, particularly in the ER-
positive/HER2-negative group.
The generic point we make here is the need to con-
sider the mechanism of action of the anti-cancer agent
being tested in the experimental arm as an important
additional factor, with potential influence on the rela-
tionship between pCR and longer-term outcomes in
neoadjuvant trials.
Do the challenges to the correlation of pCR to longer-term
outcomes invalidate neoadjuvant trials?
Clearly our answer to this is most definitely not. We
base this opinion on a thorough review of all the litera-
ture, including the most recent publications of the
exploration of the statistics behind the ALLTO/
NeoALLTO controversy [39–41] and the detailed ana-
lyses of Hatzis and colleagues [42], which demonstrate
the implications for future neoadjuvant trial designs
using complex multifactorial modelling. There is a con-
sensus, supported by evidence from Cortazar et al. [5]
and Berruti et al. [6], and agreed by the FDA for licens-
ing purposes, that neoadjuvant breast cancer trials will
have most applicability in subtypes of breast cancer that
have aggressive tumour biology and respond well to
standard or targeted treatments. At present, the neoad-
juvant literature has clearly identified triple-negative
breast cancer and HER2-positive disease as fitting these
criteria. In our view, ER-positive disease, which is low
risk on account of tumour biology, is unlikely ever to
achieve statistical correlation between pCR and longer-
term outcomes because they are more likely to be af-
fected by the multiple confounding factors described
earlier.
At present, the most notable outlier (even in high-risk
groups) in terms of good correlation between pCR and
longer-term outcomes is the NOAH trial [6, 10],
which randomised patients to standard neoadjuvant
chemotherapy with or without trastuzumab, which was
continued after surgery in the experimental arm only. This
trial was completed just before the paradigm-shifting adju-
vant trastuzumab studies demonstrated the large benefit
from adjuvant trastuzumab [43, 44]. We must remember
that in ALLTO and NeoALLTO, the question asked by
the trial was whether dual anti-HER2 therapy could im-
prove on the impressive results of these initial trastuzu-
mab studies. These ‘second order’ trials are always going
to be more of a challenge because one would not neces-
sarily expect more than a ‘marginal’ increase in benefit,
unless patients have been selected at recruitment as
poor responders to established therapy. In the event,
Neo-ALLTO showed an absolute improvement of
20 % in pCR rates, and ALLTO narrowly missed stat-
istical significance with an HR of 0.84 (97.5 %, CI
0.70–1.02), which was predicted to be HR 0.83 (Fig. 4),
potentially owing to too few patients in the relevant
comparisons. DeMichele and colleagues [41] detail
compelling and robust arguments supporting the con-
tinued use of neoadjuvant trials in high-risk HER2-
positive breast cancer. Theirs is an important generic
review of the evidence given that the vast majority of
future neoadjuvant trials in high-risk breast cancer
will be asking questions about the benefit of new tar-
geted agents in combination with standard effective
therapies. In our view, the evidence cited above strongly
supports the continuation of neoadjuvant trials as a way
of identifying the potential benefit of new agents as
quickly as possible. Perhaps more compelling is the op-
posite argument, that demonstrating lack of efficacy in a
neoadjuvant trial should prevent the vast cost of testing
the new agent in large adjuvant trials.
Hatzis and colleagues [42] have proposed that it is the
baseline prognosis of the accrued patient population that
has a major impact on the relationship between trial
arm level survival and improvement in pCR. This makes
some intuitive sense and implies that even large in-
creases in pCR rate will translate into very modest im-
provement in survival if the baseline prognosis is already
good. Both the BEATRICE and ALLTO adjuvant trials
(of bevacizumab and dual anti-HER2 therapy respect-
ively) demonstrate Hatzis’ modelling, because the trial
arms had remarkable and unexpectedly good long-term
survival outcome. In other words, to detect a long-term
outcome effect between treatment arms with credible
power, an unrealistically high pCR rate in the experi-
mental arm would be required, as well as recruitment of
more than 250 patients per treatment arm. In addition,
Hatzis and colleagues used the NOAH trial to model the
effect of using a primary endpoint that combines pCR
with RCB down-staging as a more sensitive primary end-
point. They found that it correlated significantly with
DMFS in their post hoc analysis of the NOAH trial.
Fig. 4 Expected event-free survival curves for trastuzumab as well as for
the combination of trastuzumab and lapatinib are shown based on the
NeoALTTO results. (Reproduced with permission from Clinical Cancer
Research, DeMichele et al. [41]: License Number 3666990663029)
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What about novel agents addressing unmet need in
non-responders to neoadjuvant therapy?
Rather than focusing on the responders in neoadjuvant
trials, what happens if we look at the non-responders in
terms of pathological evaluation and try to improve their
long-term outcomes? In neoadjuvant trials of high-risk
breast cancer, although pCR rates are relatively high,
there will still be a modest proportion who show no evi-
dence of response. If we assign these patients to more
neoadjuvant therapy, or additional adjuvant treatment to
try and improve their outcomes and we succeed, then
we remove any possibility of the correlation between
pCR and longer-term outcome being significant. Would
it go against good trial design and statistical planning to
do so? Our view is that the most important outcome
from a neoadjuvant trial in high-risk early breast cancer
is the primary endpoint of pathological response and
that to attempt to improve outcomes for non-responders
would be a more valid endeavour, than to insist on within-
trial validation with correlation of pathological response
and longer-term outcomes.
Summary
Neoadjuvant breast cancer trials have a great future but,
in our opinion, with some modifications to their designs.
Current neoadjuvant chemotherapy trials are not statisti-
cally powered (in terms of numbers) for longer-term
outcomes. In addition, there is an emerging consensus
that neoadjuvant chemotherapy trials are best focused
on the high-risk population. Better definition of sub-
groups will mean more clarity in terms of the primary
endpoint and perhaps more likelihood of finding a posi-
tive correlation with longer-term breast cancer-related
outcomes. As clinical research into circulating DNA is
carried out, the hope is that the definition of residual
micro-metastatic disease or the lack of it will become
more robust and therefore helpful in both the neoadju-
vant and adjuvant settings.
Novel designs for neoadjuvant trials are emerging and
the i-SPY group has led the development and implemen-
tation of adaptive Bayesian designs in neoadjuvant breast
cancer [45]. This group has now moved two novel
agents from phase 2 trials into i-SPY 3 trials [46], that
will test in the standard setting the final stage of these
elegant solutions to speeding up the introduction of new
therapies for patients with early breast cancer. Our own
group is developing Bayesian adaptive randomised de-
signs to define ‘pairs’ of novel biomarkers and new
agents [47]. Other adaptive designs in development will
focus on high-risk patients who have not achieved a
pathological response and these patients will be offered
secondary randomisations into trials of novel therapy in
the neoadjuvant and adjuvant setting. As these trials are
developed, the ‘statistical’ consequences are inevitable;
there will no longer be any possibility of positively
correlating pathological response with longer-term out-
comes, as we strive for better outcomes for patients not
achieving a pathological response to first-line neoadju-
vant treatment.
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